Global CRO signs agreement with OmniComm Systems

Seven-year TrialOne agreement expands commitment to supporting early-phase studies

DDNews Staff
FORT LAUDERDALE, Fla.—A global provider of drug development and commercialization solutions and services has signed a new agreement extending its relationship with OmniComm Systems Inc., a provider of clinical data management technology, for another seven years. Under the terms of the agreement, the contract research organization (CRO) will use OmniComm’s TrialOne eClinical solution to automate early-phase studies at one of its U.S.-based clinical research units.
The CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase 1 clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase 1 clinics.
Browser-based, tablet-compatible TrialOne streamlines and automates key processes for early-phase clinics, which drive efficiencies and reduce timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time bedside data collection, direct data capture from devices, sample processing automation and data processing. The automation reduces workload on clinic staff and improves the clinical trial experience for volunteers.
“Each new contract documents TrialOne’s position as the market-leading eSource solution for Phase 1 clinics,” said Dr. Kuno van der Post, OmniComm’s chief commercial officer. “We’re excited to continue building our partnership with this leading CRO.”

DDNews Staff

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022